Literature DB >> 18556624

The cancer paradigm of severe pulmonary arterial hypertension.

Pradeep R Rai1, Carlyne D Cool, Judy A C King, Troy Stevens, Nana Burns, Robert A Winn, Michael Kasper, Norbert F Voelkel.   

Abstract

The plexiform lesions of severe pulmonary arterial hypertension (PAH) are similar in histologic appearance, whether the disease is idiopathic or secondary. Both forms of the disease show actively proliferating endothelial cells without evidence of apoptosis. Here, we discuss the pathobiology of the atypical, angioproliferative endothelial cells in severe PAH. The concept of the endothelial cell as a "quasi-malignant" cell provides a new framework for antiproliferative, antiangiogenic therapy in severe PAH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18556624      PMCID: PMC2542431          DOI: 10.1164/rccm.200709-1369PP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  74 in total

1.  Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

Authors:  Joseph T Crossno; Chrystelle V Garat; Jane E B Reusch; Kenneth G Morris; Edward C Dempsey; Ivan F McMurtry; Kurt R Stenmark; Dwight J Klemm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-12-22       Impact factor: 5.464

2.  BMP-induced growth suppression in colon cancer cells is mediated by p21WAF1 stabilization and modulated by RAS/ERK.

Authors:  Stayce E Beck; Barbara H Jung; Eunice Del Rosario; Jessica Gomez; John M Carethers
Journal:  Cell Signal       Date:  2007-01-24       Impact factor: 4.315

Review 3.  Taking dendritic cells into medicine.

Authors:  Ralph M Steinman; Jacques Banchereau
Journal:  Nature       Date:  2007-09-27       Impact factor: 49.962

4.  Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension.

Authors:  Silvia Ulrich; Mark R Nicolls; Laima Taraseviciene; Rudolf Speich; Norbert Voelkel
Journal:  Respiration       Date:  2007-11-20       Impact factor: 3.580

5.  The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted.

Authors:  Sebastien Bonnet; Gael Rochefort; Gopinath Sutendra; Stephen L Archer; Alois Haromy; Linda Webster; Kyoko Hashimoto; Sandra N Bonnet; Evangelos D Michelakis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-27       Impact factor: 11.205

Review 6.  Metastasis: the seed and soil theory gains identity.

Authors:  Emmanouil Fokas; Rita Engenhart-Cabillic; Kiriakos Daniilidis; Frank Rose; Han-Xiang An
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 7.  Bone morphogenetic proteins and their receptor signaling in prostate cancer.

Authors:  L Ye; J M Lewis-Russell; H G Kyanaston; W G Jiang
Journal:  Histol Histopathol       Date:  2007-10       Impact factor: 2.303

8.  Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension.

Authors:  Fares A Masri; Weiling Xu; Suzy A A Comhair; Kewal Asosingh; Michelle Koo; Amit Vasanji; Judith Drazba; Bela Anand-Apte; Serpil C Erzurum
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-05-25       Impact factor: 5.464

9.  Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling.

Authors:  Laimute Taraseviciene-Stewart; Mark R Nicolls; Donatas Kraskauskas; Robertas Scerbavicius; Nana Burns; Carlyne Cool; Kathy Wood; Jane E Parr; Susan A Boackle; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2007-04-05       Impact factor: 21.405

Review 10.  Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis.

Authors:  Masaru Katoh
Journal:  Stem Cell Rev       Date:  2007-01       Impact factor: 6.692

View more
  95 in total

1.  Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans.

Authors:  Harm J Bogaard; Shiro Mizuno; Christophe Guignabert; Aysar A Al Hussaini; Daniela Farkas; Gerrina Ruiter; Donatas Kraskauskas; Elie Fadel; Jeremy C Allegood; Marc Humbert; Anton Vonk Noordegraaf; Sarah Spiegel; Laszlo Farkas; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

Review 2.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

Review 3.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 4.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

5.  Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.

Authors:  Keytam S Awad; Jason M Elinoff; Shuibang Wang; Salina Gairhe; Gabriela A Ferreyra; Rongman Cai; Junfeng Sun; Michael A Solomon; Robert L Danner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-11-20       Impact factor: 5.464

6.  ID3 contributes to the acquisition of molecular stem cell-like signature in microvascular endothelial cells: its implication for understanding microvascular diseases.

Authors:  Jayanta K Das; Norbert F Voelkel; Quentin Felty
Journal:  Microvasc Res       Date:  2015-02-07       Impact factor: 3.514

7.  Connectivity map analysis of nonsense-mediated decay-positive BMPR2-related hereditary pulmonary arterial hypertension provides insights into disease penetrance.

Authors:  Charles Flynn; Siyuan Zheng; Ling Yan; Lora Hedges; Bethany Womack; Josh Fessel; Joy Cogan; Eric Austin; James Loyd; James West; Zhongming Zhao; Rizwan Hamid
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02-03       Impact factor: 6.914

8.  Interleukin-6 overexpression induces pulmonary hypertension.

Authors:  M Kathryn Steiner; Olga L Syrkina; Narasaish Kolliputi; Eugene J Mark; Charles A Hales; Aaron B Waxman
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

Review 9.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

10.  A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

Authors:  M Gomberg-Maitland; M L Maitland; R J Barst; L Sugeng; S Coslet; T J Perrino; L Bond; M E Lacouture; S L Archer; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2009-12-09       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.